Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/Takeda To Re-start Motesanib Lung Cancer Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee
Advertisement

Related Content

Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen Submits Denosumab BLA Ahead Of Expectations
FDA Seeks Input On Acceptable Trial Design For Assessing Predictive Biomarkers
Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
Bayer/Onyx’s Nexavar Falters In Lung-Cancer Phase III

Topics

Advertisement
UsernamePublicRestriction

Register

PS004054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel